Eli Lilly and Novo Nordisk compete in a handful of different markets. Novo Nordisk is scaling up its output and upgrading its ...

The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has ...

The GLP-1 drug giant’s shares have surged this year. Eli Lilly could keep climbing thanks to strong demand for Mounjaro and ...

The rivalry between Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) has heated up as both companies vie for ...

In agreeing with Novo Nordisk and Eli Lilly, Pennsylvania judge Karen Spencer Marston said the court should first settle ...

Novo Nordisk 's ( NVO 1.19%) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is ...

Eli Lilly this week announced plans to sell single-dose vials of its weight loss drug Zepbound directly to consumers. Novo ...

President Biden and I co-authored an op-ed demanding that Novo Nordisk and Eli Lilly substantially lower the outrageously ...

Eli Lilly announced that single-dose vials of the weight-loss drug Zepbound will be sold at a discount price of 50% or more.

Eli Lilly is offering 2.5-milligram and 5-milligram single-dose vials of Zepbound for $399 per month and $549 per month, ...

Novo Nordisk and Eli Lilly, the dominant players in the GLP-1R market, are expected to collectively capture 94 per cent of ...

Eli Lilly is cutting the cost of certain weight loss drugs, with new single-dose vials costing less than other medications ...